Abstract Number: 2156 • ACR Convergence 2023
Efficacy of Olokizumab in Comorbid Depressive Disorder in Patients with Rheumatoid Arthritis: Preliminary Results of a Study
Background/Purpose: Interleukin-6 (IL) plays an important role in the pathogenesis of comorbid rheumatoid arthritis (RA) depression, and IL-6 inhibitors used to treat RA patients may…Abstract Number: 2258 • ACR Convergence 2023
Brain Activity Patterns and Behavioural Performance in SLE Patients During a Spatial Working Memory and Sustained Attention Task
Background/Purpose: Cognitive impairment (CI) is a significant problem in SLE but there is a disconnect between objective and subjective CI. This makes it difficult to…Abstract Number: 2259 • ACR Convergence 2023
The Effects of Systematic Lupus Erythematosus Related Cognitive Impairments on Activities of Daily Living and Life Role Participation: A Qualitative Framework Study
Background/Purpose: Cognitive impairment (CI) in systemic lupus erythematosus (SLE) negatively impacts health-related quality of life leading to activity limitations. This qualitative study aimed to (1)…Abstract Number: 2290 • ACR Convergence 2023
Association of Mycophenolate and Azathioprine Use with Cognitive Function in Systemic Lupus Using a Bayesian Longitudinal Item-response Theory Model
Background/Purpose: Cognitive dysfunction (CD) is a common and often deleterious manifestation of systemic lupus erythematosus (SLE). CD is usually operationalized on the American College of…Abstract Number: 0417 • ACR Convergence 2023
The Role of Rheumatoid Arthritis Flare in the Risk of Alzheimer’s Disease and Related Dementias: A Population-based Cohort Study
Background/Purpose: Patients with rheumatoid arthritis (RA) have increased risk for Alzheimer's disease and related dementias (AD/ADRD). Recent studies have reported an association between RA disease…Abstract Number: 2303 • ACR Convergence 2023
Are Neuropsychiatric Symptoms in Systemic Lupus Erythematosus (NPSLE) Associated with More Frequent Hospitalizations or Exposure to a Greater Number of Immunosuppressive Medications?
Background/Purpose: Neuropsychiatric (NP) symptoms occur in >50% of patients with systemic lupus erythematosus (SLE). A major barrier to research includes the non-specific nature of neuropsychiatric…Abstract Number: 0549 • ACR Convergence 2023
Development of Customized Digital Cognitive Assessment Battery: A Pilot Use Case in SLE Patients
Background/Purpose: Reported prevalence of cognitive dysfunction (CD) in SLE varies from 3%-88%1.Variability may be due to use of tools insensitive to population characteristics like literacy,…Abstract Number: 2446 • ACR Convergence 2023
Intermittent Fasting Attenuates Cognitive Dysfunction in Murine Systemic Lupus Erythematosus
Background/Purpose: Cognitive dysfunction is one of the most common manifestations of neuropsychiatric systemic lupus erythematosus (NPSLE) and severely affects patients' health-related quality of life. Intermittent…Abstract Number: 0558 • ACR Convergence 2023
Elevated Serum Levels of S100A8/A9 Discriminate Systemic Lupus Erythematosus Patients with Cognitive Impairment from Patients Without Impairment
Background/Purpose: Cognitive impairment (CI) is one of the most common manifestations of Neuropsychiatric Systemic Lupus Erythematosus (NPSLE). Studies have reported that SLE patients with different…Abstract Number: 2449 • ACR Convergence 2023
Cognitive Functioning Among Individuals with Systemic Lupus Erythematosus: A Population-Based Study
Background/Purpose: Studies of objectively measured cognitive dysfunction in SLE are often limited by small sample size, limited generalizability, and lack of diversity. We sought to…Abstract Number: 1219 • ACR Convergence 2023
Patient Experience of Brain Fog to Inform the Development of a De Novo Patient Reported Outcome (PRO) in Patients with Sjögren’s Disease
Background/Purpose: Brain fog is commonly reported by SJD patients, though limited evidence exists to understand patient experiences. Various terms may be used to describe brain…Abstract Number: 1226 • ACR Convergence 2023
Examining the Relationship Between Socioenvironmental Factors and Cognitive Functioning in Youth with Childhood-Onset Systemic Lupus Erythematosus
Background/Purpose: Problems with cognitive functioning are common in childhood-onset systemic lupus erythematosus (cSLE); these may be attributed to many factors including underlying brain inflammation. Socioenvironmental…Abstract Number: 1229 • ACR Convergence 2023
Longitudinal Assessment of Self-reported Executive Function in Youth with Childhood-Onset Lupus
Background/Purpose: Cognitive dysfunction (including executive dysfunction) affects up to 60% of youth with childhood-onset systemic lupus erythematosus (cSLE), with potential adverse effects on health-related quality…Abstract Number: 1241 • ACR Convergence 2023
Adverse Childhood Experiences in a Paediatric Systemic Lupus Erythematosus Cohort
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic, multiorgan autoimmune disease in which 20% of cases are diagnosed in childhood. Adverse childhood experiences (ACEs) are…Abstract Number: 1242 • ACR Convergence 2023
Agreement Between Parent- and Self-Report of Executive Function in Adolescents with Childhood-Onset Systemic Lupus Erythematosus
Background/Purpose: Executive functions (EFs) are a set of cognitive skills that enable successful problem solving and goal-directed behavior. EFs are predictive of academic success, mental…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 9
- Next Page »